GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (NAS:COCP) » Definitions » Revenue

Cocrystal Pharma (Cocrystal Pharma) Revenue : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Cocrystal Pharma Revenue?

Cocrystal Pharma's revenue for the three months ended in Dec. 2023 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Cocrystal Pharma's Revenue per Share for the three months ended in Dec. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Cocrystal Pharma's highest 3-Year average Revenue per Share Growth Rate was -93.20% per year. The lowest was -93.20% per year. And the median was -93.20% per year.


Cocrystal Pharma Revenue Historical Data

The historical data trend for Cocrystal Pharma's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cocrystal Pharma Revenue Chart

Cocrystal Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.56 2.01 - - -

Cocrystal Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cocrystal Pharma's Revenue

For the Biotechnology subindustry, Cocrystal Pharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cocrystal Pharma's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Revenue distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's Revenue falls into.



Cocrystal Pharma Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cocrystal Pharma  (NAS:COCP) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Cocrystal Pharma Revenue Related Terms

Thank you for viewing the detailed overview of Cocrystal Pharma's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cocrystal Pharma (Cocrystal Pharma) Business Description

Traded in Other Exchanges
Address
19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Executives
Fred Hassan director C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Frost Phillip Md Et Al director, 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Raymond F Schinazi director, 10 percent owner 1860 MONTREAL ROAD, TUCKER GA 30084
Anthony J Japour director 19805 N. CREEK PARKWAY, BOTHELL WA 98011
Todd R. Brady director 19805 N. CREEK PARKWAY, BOTHELL WA 98011
James Joseph Martin officer: Interim CFO 4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Curtis Dale officer: INTERIM CFO 1860 MONTREAL ROAD, TUCKER GA 30084
Douglas L Mayers officer: CHIEF MEDICAL OFFICER C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Walt Addison Linscott officer: GENERAL COUNSEL AND SECRETARY 1860 MONTREAL ROAD, TUCKER GA 30084
Jeffrey A Meckler director 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
David S Block director
Hsiao Jane Ph D director 4400 BISCAYNE BLVD, MIAMI FL 33137
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Roger D. Kornberg director 345 WALSH ROAD, ATHERTON CA 94027

Cocrystal Pharma (Cocrystal Pharma) Headlines

From GuruFocus